SERPINE1 rs6092 Variant Is Related to Plasma Coagulation Proteins in Patients with Severe COVID-19 from a Tertiary Care Hospital
Por:
Fricke-Galindo, Ingrid, Buendia-Roldan, Ivette, Chavez-Galan, Leslie, Perez-Rubio, Gloria, Hernandez-Zenteno, Rafael de Jesus, Ramos-Martinez, Espiridion, Zazueta-Marquez, Armando, Reyes-Melendres, Felipe, Alarcon-Dionet, Aime, Guzman-Vargas, Javier, Bravo-Gutierrez, Omar Andres, Quintero-Puerta, Teresa, Gutierrez-Perez, Ilse Adriana, Ortega-Martinez, Alejandro, Ambrocio-Ortiz, Enrique, Nava-Quiroz, Karol J., Banuelos-Flores, Jose Luis, Jaime-Capetillo, Maria Esther, Mejia, Mayra, Rojas-Serrano, Jorge, Falfan-Valencia, Ramces
Publicada:
1 abr 2022
Resumen:
Simple Summary Severe forms of coronavirus disease 2019 (COVID-19) are
related to an alteration in the coagulation process determined by
genetic factors. Variability on F5 and SERPINE1 genes has been
previously reported as a risk factor for thrombosis associated with
different diseases. In this study, we aimed to evaluate if two relevant
variants in the F5 and SERPINE1 genes were related to the requirement of
invasive mechanical ventilation in hospitalized patients with COVID-19
and/or the levels of coagulation-related proteins. We observed that
patients presenting the studied variants in F5 and SERPINE1 exhibit
different levels of coagulation-related proteins. Moreover, the levels
of these proteins were higher among patients requiring invasive
mechanical ventilation when compared to hospitalized patients with no
ventilation support. This study contributes to the genetics insight
regarding COVID-19 severity and the inter-individual susceptibility for
a severe form of the infectious disease. An impaired coagulation process
has been described in patients with severe or critical coronavirus
disease (COVID-19). Nevertheless, the implication of coagulation-related
genes has not been explored. We aimed to evaluate the impact of F5
rs6025 and SERPINE1 rs6092 on invasive mechanical ventilation (IMV)
requirement and the levels of coagulation proteins among patients with
severe COVID-19. Four-hundred fifty-five patients with severe COVID-19
were genotyped using TaqMan assays. Coagulation-related proteins
(P-Selectin, D-dimer, P-selectin glycoprotein ligand-1, tissue
plasminogen activator [tPA], plasminogen activator inhibitor-1, and
Factor IX) were assessed by cytometric bead arrays in one- and two-time
determinations. Accordingly, SERPINE1 rs6092, P-Selectin (GG 385 pg/mL
vs. AG+AA 632 pg/mL, p = 0.0037), and tPA (GG 1858 pg/mL vs. AG+AA 2546
pg/mL, p = 0.0284) levels were different. Patients carrying the CT
F5-rs6025 genotype exhibited lower levels of factor IX (CC 17,136 pg/mL
vs. CT 10,247 pg/mL, p = 0.0355). Coagulation proteins were also
different among IMV patients than non-IMV. PSGL-1 levels were
significantly increased in the late stage of COVID-19 (>10 days). The
frequencies of F5 rs6025 and SERPINE1 rs6092 variants were not different
among IMV and non-IMV. The SERPINE1 rs6092 variant is related to the
impaired coagulation process in patients with COVID-19 severe.
Filiaciones:
Fricke-Galindo, Ingrid:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Buendia-Roldan, Ivette:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Translat Res Lab Aging & Pulm Fibrosis, Mexico City 14080, DF, Mexico
Chavez-Galan, Leslie:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab Integrat Immunol, Mexico City 14080, DF, Mexico
Perez-Rubio, Gloria:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Hernandez-Zenteno, Rafael de Jesus:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, COPD Clin, Mexico City 14080, DF, Mexico
Ramos-Martinez, Espiridion:
Univ Nacl Autonoma Mexico, Fac Med, Unidad Invest Med Expt, Mexico City 06720, DF, Mexico
Zazueta-Marquez, Armando:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Reyes-Melendres, Felipe:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Alarcon-Dionet, Aime:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Translat Res Lab Aging & Pulm Fibrosis, Mexico City 14080, DF, Mexico
Guzman-Vargas, Javier:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Bravo-Gutierrez, Omar Andres:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Quintero-Puerta, Teresa:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Gutierrez-Perez, Ilse Adriana:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Ortega-Martinez, Alejandro:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Ambrocio-Ortiz, Enrique:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Nava-Quiroz, Karol J.:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Banuelos-Flores, Jose Luis:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Clin Lab Serv, Mexico City 14080, DF, Mexico
Jaime-Capetillo, Maria Esther:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Clin Lab Serv, Mexico City 14080, DF, Mexico
Mejia, Mayra:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Pulm Dis & Rheumatol Unit, Mexico City 06720, DF, Mexico
Rojas-Serrano, Jorge:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Pulm Dis & Rheumatol Unit, Mexico City 06720, DF, Mexico
Falfan-Valencia, Ramces:
Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Mexico City 14080, DF, Mexico
Green Published, gold, Gold, Green
|